Phoenix, AZ, September 22, 2026 — Hundreds of lawsuits have been initiated against pharmaceutical companies Eli Lilly and Novo Nordisk. The legal actions center on allegations that popular GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, have led to permanent vision loss and other eye damage.

Plaintiffs in these suits claim that the drugs caused a specific condition known as NAION (non-arteritic anterior ischemic optic neuropathy). According to a report by AZFamily/Gray News, based in Phoenix, these alleged adverse effects are not currently documented on the U.S. warning labels for these widely prescribed medications.

Eli Lilly and Novo Nordisk, the manufacturers of these drugs, have reportedly denied a significant connection between their GLP-1 medications and the reported instances of vision loss. The scope of the alleged harm and the number of affected individuals are detailed through the filing of hundreds of lawsuits.

Information regarding the specific timeline of when these lawsuits were filed, the exact number of plaintiffs, or the potential outcomes of these legal proceedings was not immediately available. The status of the alleged side effects on U.S. warning labels, as reported by AZFamily/Gray News, indicates they are not presently listed. Further details on the legal proceedings or the companies’ responses are ongoing.


Story summarized from the original created by Micaela Marshall, Gray News staff, azfamily staff on www.azfamily.com, see more information here.

Media gallery

About The Author
SignalNewsAI